#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #glofitamab

ADC Therapeutics Announces LOTIS-7 Clinical Trial Update

ADC Therapeutics SA (NYSE: ADCT) has scheduled a live conference call and webcast for December 11, 2024, at 8:30 a.m. EST. The event will present preliminary findings from the LOTIS-7 Phase 1b open-label clinical trial. This important trial is evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

During the call, stakeholders will gain insights into the early data, which promises to further inform the treatment landscape for patients grappling with this challenging hematologic malignancy. The conference call can be accessed via a specific registration link provided by the company. For convenience, participants from North America and Canada can dial in toll-free at 1-800-836-8184. It is advisable for attendees to join the call 10 minutes prior to the start time, although pre-registration is available at any moment.

A live webcast will be available under the “Events and Presentations” section on the ADC Therapeutics Investors page, ensuring that those unable to join live can catch up with the detailed discussions later. The archived version of the webcast will remain accessible for 30 days post-event, providing ample opportunity for review.

About ADC Therapeutics

ADC Therapeutics stands as a leading innovator in the field of antibody-drug conjugates (ADCs). It is dedicated to advancing proprietary ADC technology, with a goal to redefine treatment approaches for patients facing hematologic malignancies and solid tumors. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), recently obtained accelerated approval from the FDA and conditional approval from the European Commission specifically for treating relapsed or refractory diffuse large B-cell lymphoma found in patients after two or more lines of systemic therapy.

Currently, ZYNLONTA is also being investigated in collaboration with additional agents and across various treatment contexts. Besides ZYNLONTA, ADC Therapeutics boasts a diverse portfolio of ADCs that are in various stages of clinical and preclinical development, showcasing the company’s relentless commitment to pioneering new therapeutic avenues.

Operating from Lausanne (Biopôle), Switzerland, ADC Therapeutics maintains additional facilities in London and New Jersey, nurturing its global reach in the biotechnology sector. For further details, stakeholders are encouraged to explore the ADC’s official website or engage with the company on LinkedIn.

Conclusion

As December 11 approaches, the anticipation surrounding ADC Therapeutics’ update from the LOTIS-7 clinical trial is palpable within the healthcare community. The findings shared during the conference call are expected to generate significant discussions regarding the evolving treatment dynamics for patients with advanced lymphoma and could pave the way for future innovations in cancer therapy.